Drug Trial Radar · NCT03322540
Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)
Last checked: Nov 19, 2026Latest source record: Aug 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
154
Actual
Start
Dec 15, 2017
Primary completion
Jan 10, 2019
Study completion Nov 9, 2020
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Oct 26, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to pembrolizumab plus placebo as first-line treatment in participants with metastatic non-small cell lung cancer (NSCLC) expressing high levels of programmed cell death ligand 1 (PD-L1).
Conditions
- Lung Cancer
Interventions
PembrolizumabDrug
Pembrolizumab administered intravenously every 3 weeks.
EpacadostatDrug
Epacadostat administered orally twice daily.
PlaceboDrug
Matching placebo administered orally twice daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) of Pembrolizumab Plus Epacadostat Versus Pembrolizumab Plus PlaceboTime frame: Up to approximately 6 months
Locations
101 sites in 18 countries. Site status is shown where the registry gives one.
Pacific Cancer Medical Center, Inc.
Anaheim, California
Innovative Clinical Research Institute
Whittier, California
Florida Cancer Specialists (South Region)
Fort Myers, Florida
Florida Cancer Specialists (North Region)
St. Petersburg, Florida
Southeastern Regional Medical Center, Inc.
Newnan, Georgia
Anne Arundel Health System Research Institute
Annapolis, Maryland
Weinberg Cancer Institute at Franklin Square
Baltimore, Maryland
Maryland Oncology Hematology, P.A.
Rockville, Maryland
UMass Memorial Medical Center
Worcester, Massachusetts
Minnesota Oncology Hematology, PA
Coon Rapids, Minnesota
Nebraska Cancer Specialists
Omaha, Nebraska
Allegheny General Hospital
Pittsburgh, Pennsylvania
Tennessee Oncology, PLLC/The Sarah Cannon Research Institute
Chattanooga, Tennessee
Tennessee Oncology, PLLC/The Sarah Cannon Research Institute
Nashville, Tennessee
Texas Oncology-South Austin
Austin, Texas
Austin Health-Austin Hospital
Heidelberg, Victoria, Australia
St John of God Murdoch Medical Clinic
Murdoch, Western Australia, Australia
Cross Cancer Institute
Edmonton, Alberta, Canada
Moncton Hospital - Horizon Health Network
Moncton, New Brunswick, Canada
William Osler Health System
Brampton, Ontario, Canada
Cancer Centre of Southeastern Ontario at Kingston General Hospital
Kingston, Ontario, Canada
Sault Area Hospital
Sault Ste. Marie, Ontario, Canada
Rigshospitalet
Copenhagen, Denmark
Regionshospitalet Herning
Herning, Denmark
Odense Universitetshospital
Odense, Denmark
SA Tartu Ulikooli Kliinikum
Tartu, Estonia
St Vincents University Hospital
Dublin, Ireland
Galway University Hospital
Galway, Connacht, Ireland
Soroka Medical Center
Beersheba, Israel
Rambam Medical Center
Haifa, Israel
Meir Medical Center
Kfar Saba, Israel
Rabin Medical Center
Petah Tikva, Israel
Chaim Sheba Medical Center
Ramat Gan, Israel
IRCCS A.O.U. San Martino - IST
Genova, Italy
Policlinico Universitario Agostino Gemelli
Roma, Italy
National Hospital Organization Kyushu Cancer Center
Fukuoka, Japan
Kyushu University Hospital
Fukuoka, Japan
Niigata Cancer Center Hospital
Niigata, Japan
Okayama University Hospital
Okayama, Japan
National Cancer Center Hospital
Tokyo, Japan
Showing 40 of 101 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.